Effectiveness of a third dose of BNT162b2 anti-SARS-CoV-2 mRNA vaccine over a 6-month follow-up period in allogenic hematopoietic stem cells recipients.

Patrice ChevallierMaxime JullienPierre PeterlinAlice GarnierAmandine Le BourgeoisMarianne Coste-BurelMarie Christine BeneThierry Guillaume

Published in: Hematological oncology (2022)

This study reports the effectiveness of three injections of BNT162b2 anti-SARS-CoV-2 mRNA vaccine in 141 Allo-HSCT recipients with a median follow-up of 6 months post-third shot. We demonstrate a long-term high protection of Allo-HSCT recipients since only 2 infections and one death related to COVID-19 occurred.

Keyphrases

sars cov
stem cells
respiratory syndrome coronavirus
kidney transplantation
randomized controlled trial
systematic review
hematopoietic stem cell
binding protein
bone marrow
coronavirus disease
emergency department
ultrasound guided
adverse drug